ASSESSMENT OF INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。为了确定嗜中性粒细胞、活性弹性蛋白酶和细胞因子在高渗盐水诱导的痰液中测量是否是有用的筛选试验，以确定具有已知抗炎特性的特定药物是否适合用于CF患者的更广泛的临床试验。这一目标将通过一种抗炎药物布洛芬（已被证明对CF具有临床益处）和一种抗炎药物塞来昔布（celecoxib）来解决。有可能对CF有临床益处的药物。无治疗组作为对照组。对临床稳定的CF患者进行为期4周的治疗前（基线期）、治疗期间（治疗期）和恢复期后（恢复期）的诱导痰标本评估。将评估每个分支内部和分支之间的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using one anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF, and one anti-inflammatory agent, celecoxib, that has potential to have clinical benefit in CF. A ¿no treatment¿ arm will be included as the control group. The outcome measures will be assessed in induced sputum specimens before (Baseline Period), during (Treatment Period), and after (recovery Period) a 4-week treatment period in clinically stable CF patients. Changes will be assessed within each arm and between arms.